EA201690754A1 - Применение ингибитора pcsk9 для лечения гиперлипидемии - Google Patents
Применение ингибитора pcsk9 для лечения гиперлипидемииInfo
- Publication number
- EA201690754A1 EA201690754A1 EA201690754A EA201690754A EA201690754A1 EA 201690754 A1 EA201690754 A1 EA 201690754A1 EA 201690754 A EA201690754 A EA 201690754A EA 201690754 A EA201690754 A EA 201690754A EA 201690754 A1 EA201690754 A1 EA 201690754A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pcsk9 inhibitor
- hyperlipidemia
- treatment
- application
- pcsk9
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
Abstract
Настоящее изобретение относится к способам лечения гиперлипидемии у пациентов, которые не получают терапию статинами. Способы по настоящему изобретению включают введение пациенту фармацевтической композиции, содержащей ингибитор PCSK9. В определенных вариантах осуществления ингибитор PCSK9 представляет собой антитело против PCSK9, такое как иллюстративное антитело, обозначаемое в настоящем описании как mAb316Р.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890154P | 2013-10-11 | 2013-10-11 | |
US201461923103P | 2014-01-02 | 2014-01-02 | |
US201461955514P | 2014-03-19 | 2014-03-19 | |
US201462004620P | 2014-05-29 | 2014-05-29 | |
US201462025104P | 2014-07-16 | 2014-07-16 | |
EP14306221 | 2014-07-31 | ||
US201462054571P | 2014-09-24 | 2014-09-24 | |
EP14306584 | 2014-10-09 | ||
PCT/US2014/060109 WO2015054619A2 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690754A1 true EA201690754A1 (ru) | 2016-10-31 |
EA037526B1 EA037526B1 (ru) | 2021-04-08 |
Family
ID=52813751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690754A EA037526B1 (ru) | 2013-10-11 | 2014-10-10 | Применение ингибитора pcsk9 для лечения гиперлипидемии |
Country Status (14)
Country | Link |
---|---|
US (1) | US20150140002A1 (ru) |
EP (2) | EP3055333B1 (ru) |
JP (2) | JP6846931B2 (ru) |
KR (3) | KR20230119045A (ru) |
CN (3) | CN115192704A (ru) |
AU (2) | AU2014331754B2 (ru) |
CA (1) | CA2926942A1 (ru) |
EA (1) | EA037526B1 (ru) |
ES (1) | ES2914978T3 (ru) |
IL (1) | IL244995B (ru) |
MX (3) | MX2016004580A (ru) |
PL (2) | PL3055333T4 (ru) |
TW (1) | TWI669131B (ru) |
WO (1) | WO2015054619A2 (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2012101253A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
CN111789944A (zh) | 2011-09-16 | 2020-10-20 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TW201534324A (zh) | 2013-06-07 | 2015-09-16 | Sanofi Sa | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
JP6616298B2 (ja) | 2013-11-12 | 2019-12-04 | サノフィ・バイオテクノロジー | Pcsk9阻害剤と共に使用するための投薬レジメン |
EP3169710A1 (en) * | 2014-07-14 | 2017-05-24 | Amgen Inc. | Crystalline antibody formulations |
KR20170029613A (ko) | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
CN107635512A (zh) * | 2015-04-15 | 2018-01-26 | 康斯瓦维有限责任公司 | 用于抑制天然心脏瓣膜、被支撑的心脏瓣膜或生物假体的狭窄、阻塞或钙化的装置和方法 |
CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
MA42657A (fr) * | 2015-08-18 | 2018-06-27 | Regeneron Pharma | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines |
US11111313B2 (en) | 2016-09-20 | 2021-09-07 | WuXi Biologics Ireland Limited | Anti-PCSK9 antibodies |
WO2018189705A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
US20200131576A1 (en) | 2017-04-25 | 2020-04-30 | The Brigham And Women's Hospital, Inc. | IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis |
CN107090474A (zh) * | 2017-05-22 | 2017-08-25 | 山东大学 | 一种腹主动脉瘤疾病动物模型的制备方法 |
CN109963877B (zh) * | 2017-06-14 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
KR20200129127A (ko) * | 2018-03-06 | 2020-11-17 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도 |
EP3911648A4 (en) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | PCSK9 INHIBITORS AND METHODS OF USE THEREOF |
KR20220107210A (ko) * | 2019-11-18 | 2022-08-02 | 에이디 파마슈티컬스 컴퍼니 리미티드 | 항-pcsk9 항체 및 그의 용도 |
WO2021119321A1 (en) * | 2019-12-10 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
CN114277032A (zh) * | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | 一种低密度脂蛋白受体基因突变体及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8357371B2 (en) * | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2012101253A1 (en) * | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
CN111789944A (zh) * | 2011-09-16 | 2020-10-20 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
-
2014
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Application Discontinuation
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 MX MX2016004580A patent/MX2016004580A/es active IP Right Grant
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Application Discontinuation
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active IP Right Cessation
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en active Application Filing
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
-
2016
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
-
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
-
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
PH12016502355A1 (en) | Pharmaceutical composition | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
EA201300558A1 (ru) | Соединения и способы для купирования боли | |
EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
MX2015014596A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
BR112014016805A8 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
EA201590332A1 (ru) | Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа | |
EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
PH12016502352A1 (en) | Pharmaceutical composition | |
EA201491500A1 (ru) | Способы лечения фиброза | |
TW201613578A (en) | Pharmaceutical combinations | |
EA201491875A1 (ru) | Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
EA201490495A1 (ru) | Новые легкоразрушающиеся ингибиторы rock | |
EA201691299A1 (ru) | Применение лахинимода для замедления прогрессирования болезни хантингтона |